GDTC — CytoMed Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $26.75m
- $22.09m
- 44
- 27
- 74
- 46
Annual income statement for CytoMed Therapeutics, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.851 | 1.94 | 2.05 | 3.13 | 4.13 |
| Operating Profit | -0.851 | -1.94 | -2.05 | -3.13 | -4.13 |
| Net Income Before Taxes | -0.851 | -1.94 | -2.05 | -3.13 | -4.13 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.851 | -1.94 | -2.05 | -3.13 | -4.13 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.851 | -1.94 | -2.05 | -3.13 | -4.13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.851 | -1.94 | -2.05 | -3.13 | -4.13 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.078 | -0.179 | -0.188 | -0.272 | -0.389 |
| Dividends per Share |